grantGrants.gov

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Organization National Institutes of HealthPosted 22 Nov 2024Deadline 19 Nov 2026
HHS-NIH1193.242synopsis
Sign up free to applyFree account · Full description · Apply link · All opportunity types

Full Description

Opportunity Number: PAR-25-226 Document Type: synopsis CFDA Numbers: 93.242

Read the full description

Sign up freeFree account · No credit card required
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) — National Institutes of Health | Dev Procure